Prevalence of clinically significant microvascular (green) and clinically significant macrovascular (yellow) disease alone and combined microvascular and.

Slides:

Advertisements

Similar presentations

BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.

Advertisements

Prevalence of Diabetic Retinopathy In Diabetic patients cared for at the Family Care Center at RCRMC Kam Chan, DO [ role of BP & glycemic control ]

UKPDS Paper 35 Slides © University of Oxford Diabetes Trials Unit

Diabetic Microvascular Disease: The Role of Glycemic Control and the Impact on Public Health Robert E. Ratner, MD MedStar Research Institute Georgetown.

Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.

What does it mean to our patients? Presenter: CF Otieno Affiliation: Department of Clinical Medicine and Therapeutics,UoN & KNH-Medicine.

Microvascular and Macrovascular Complications in Hispanic Americans.

Consider testing if person is: – Overweight or obese with additional risk factor for diabetes – Age 45 or older Obtain: A1C or FPG or 2-hour plasma glucose.

UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP

Long-Term Complications and Mortality in Young-Onset Diabetes Type 2 diabetes is more hazardous and lethal than type 1 diabetes Featured Article: Maria.

Impact of Diabetes on Cardiovascular Risk C.Richard Conti M.D. MACC Oct 16,2004 GWICC Beijing, PRC.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Prevalence of Diabetic Retinopathy

Discontinuation of medication after nonfatal event: MI

Volume 20, Issue 7, Pages (July 2017)

Volume 385, Issue 9985, Pages (June 2015)

366 میلیون نفر در جهان مبتلا به دیابت هستند.

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Glycemic thresholds for subjective symptomatic awareness of hypoglycemia and for the onset of cognitive dysfunction in young and elderly nondiabetic males.

Nat. Rev. Cardiol. doi: /nrcardio

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

A schematic representation of the effects of early intensive glycemic control in preventing initial microvascular complications and then macrovascular.

Prevalence of microvascular and macrovascular complications compared between cohort 1 and cohort 2 for subjects with type 2 (A, upper panel) and type 1.

Effects of Pay-for-Performance on the Quality of Primary Care in England Mean Scores for Clinical Quality at the Practice Level for Aspects of Care for.

(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,

Difference in the prevalence of sarcopenia and its components (low muscle strength and low muscle mass) between NDR, NPDR and PDR. NDR, no diabetic retinopathy;

A: Kaplan-Meier curves depicting the cumulative probability of CVE in patients with low (

Incidence rates and HRs for total cardiovascular events and stroke stratified by the TCF7L2-rs polymorphism and the dietary intervention group after.

Sensitivity analysis: random-effects model of the risk of lower extremity amputation (LEA) in people with diabetes associated with depression compared.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Study protocol. Study protocol. Fourteen patients had research renal biopsies, and 17 patients with macroalbuminuria had renal biopsies for clinical reasons.

Mean mesangial area (micron2) across normal controls (normal C), patients with type 2 diabetes and normoalbuminuria (normo), patients with type 2 diabetes.

The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

Schematic overview of diabetes-associated microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (cerebrovascular, coronary artery,

Prevalence of high SAT or high VAT by BMI category in women (A) and men (B) and by waist circumference category in women (C) and men (D). Prevalence of.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Forefoot peak plantar pressure in diabetic patients without and with mild, moderate, and severe peripheral neuropathy. *Severe and moderate neuropathy.

Plasma levels of GLP-1 are increased in patients with critical illness and correlate with disease severity. Plasma levels of GLP-1 are increased in patients.

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

For patients with type 2 diabetes and DN, follow-up time was divided into time spent in the following clinical states: DN, CVD, and ESRD in chronologic.

Study design (A) and patient disposition (B).

Trends in mortality by age-groups and select CVDs among adults with diabetes. Trends in mortality by age-groups and select CVDs among adults with diabetes.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

RBP4 and glucose metabolism.

A: Probability of retinopathy-free survival.

The prevalence of cerebral infarction in the subjects with zero to seven proatherothrombotic alleles. The prevalence of cerebral infarction in the subjects.

Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects.

Prevalence of nephropathy, retinopathy, and neuropathy in subjects achieving all (A) three targets, (B) two targets, (C) one target, and (D) none, and.

Predicted, unadjusted prevalence of aggregate MVD (retinopathy, nephropathy, and/or neuropathy) (A), nephropathy (B), retinopathy (C), and neuropathy (D)

Differences in the values of HbA1c variables between the retinopathy-positive and retinopathy-negative groups at year 20. Differences in the values of.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

Complex association between Hb level and GFR, sex, and AER

GDF-15 levels in progressors and nonprogressors in albuminuria (case and control subjects) for patients with T2DM and nondiabetic patients with HT. A:

Relationship between updated systolic blood pressure (SBP), right, and updated HbA1c, left, and the incidence of microvascular complications (closed symbols)

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

The solid line represents the point estimate of the treatment ORs at various levels along the x-axis that ranges from the minimum to the maximum observed.

Few patients with youth-onset type 2 diabetes are available to participate in clinical trials. Few patients with youth-onset type 2 diabetes are available.

Presentation transcript:

Prevalence of clinically significant microvascular (green) and clinically significant macrovascular (yellow) disease alone and combined microvascular and macrovascular disease combined (red) in patients with GCK-MODY (GCK), control subjects, and patients with young-onset type 2 diabetes (YT2D). Prevalence of clinically significant microvascular (green) and clinically significant macrovascular (yellow) disease alone and combined microvascular and macrovascular disease combined (red) in patients with GCK-MODY (GCK), control subjects, and patients with young-onset type 2 diabetes (YT2D). Clinically significant microvascular disease, defined as greater than background retinopathy or persistent microalbuminuria or proteinuria; clinically significant macrovascular disease, defined as intermittent claudication, amputation, angina, myocardial infarction, or stroke. Ali J. Chakera et al. Dia Care 2015;38:1383-1392 ©2015 by American Diabetes Association